12 results
ARS
2023 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
4:27pm
injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in: the inability or delay … comparable foreign regulatory authorities. During the conduct of clinical trials, subjects report changes in their health, including illnesses, injuries
ARS
2022 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 23
Annual report to shareholders
4:08pm
candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may … authorities. During the conduct of clinical trials, subjects report changes in their health, including illnesses, injuries, and discomforts
10-K
b1ccdfekn3cw3jeho
31 Mar 21
Annual report
5:01pm
10-Q
4byit5
24 Nov 20
Quarterly report
9:27pm
424B4
47j4z5y5
16 Oct 20
Prospectus supplement with pricing info
4:40pm
S-1/A
s1myw2fjq7aca0m
9 Oct 20
IPO registration (amended)
5:16pm
S-1
hls4cdxj
25 Sep 20
IPO registration
5:25pm
DRS/A
30h9cpq9
14 Sep 20
Draft registration statement (amended)
12:00am
DRS
dlkdgirn b2
7 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next